Clinical Trials Browser

Active not recruiting × Hodgkin Disease × Ifosfamide × Clear all

NCT03016871 2026-05-28

Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL

Phase 2 Active not recruiting

78 enrolled 15 charts

Hodgkin Disease